Hinova Pharmaceuticals Inc.

¥33.61As of Sun 8 Nov 2026, 12:00 UTC
SSE:688302Healthcare
Country China
PE (Fwd) •••
TSR 5Y CAGR 3.65%
Div yield —
ROE (13.43%)
Biotechnology
Beta (5Y) (0.01)
PE TTM —
TSR TTM (32.08%)
Mkt cap ¥3.328B
ROIC (9.56%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
¥36
7.45%
(54.19%)
Hold 6|3|1|2|3
4Q25
1Q26
2Q26
3Q26
Earnings per share¥
0.46
0.47
0.51
0.57
32.87%
34.56%
32.26%
32.56%
Revenue¥M
188.1
198.4
192.7
196.7
5.17%
5.82%
4.22%
2.34%
Peers (US$498.9M)
Cap (US$)
PE
506.5M
66.46x
497.2M
623.0x
Capital
TTM
5Y
10Y
Leveragex
0.236
(0.348)
(0.378)
EBIT/Intx
1.433
0.832
0.776
Own earn%
(48.20)
57.65
46.92
Sh yield%
25.54
50.56
44.14
Owners
Insiders/Inst%
1.31
38.34
Short interest%
5.02
SBC / revenue%
5.08
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
4
Op margin range%
28–33
$1 testx
—
Incr. ROIC%
2